PIL seeks sale of vaccines by SII, Bharat Biotech at Rs 150
   Date :29-Apr-2021

Bharat Biotech _1 &n
A PUBLIC interest litigation (PIL) has been filed in the Bombay High Court challenging the different rates for COVID-19 vaccines for the Centre and State Governments and requesting direction to the Serum Institute of India (SSI) and Bharat Biotech to sell their vaccines at a uniform rate of Rs 150 per dose. The PIL, filed on April 24 by advocate Fayzan Khan and three law students, said the vaccine is presumed to be an essential commodity and hence its management and distribution cannot be left in the hands of private companies.
“These pharma giants are milking the fear psychosis of the increased death rates due to COVID-19,” it said. The PIL also questioned the propriety of (the Centre) in asking State Governments to compete in the open market for vaccines.